Alibaba-backed genetic testing and digital health company Prenetics has acquired UK-based consumer genetic testing firm DNAFit, the latest in a series of Chinese investments in U.K healthcare assets.
Chinese orthopaedic implant company AK Medical Holdings Limited has announced the acquisition of JRI Orthopaedics Limited, a U.K. firm that designs, manufactures and supplies orthopaedic implants and related instruments, from Orthopaedic Research UK for £16.73 million (US$23.7 million).
CMB International Capital Corporation Ltd, a wholly-owned subsidiary of China Merchants Bank, has led a RMB410 million (US$65 million) series C round in Beijing Biocytogen Co., Ltd., a gene targeted animal model and service supplier.
Chinese specialty hospital management solution provider Concord Medical Services Holdings Limited (NYSE: CCM), has announced that CICC Capital Management Company Limited, a wholly-owned subsidiary of China International Capital Corporation Limited, will lead a strategic investment of between RMB1.5 billion (US$238.5 million) and RMB1.8 billion (US$286.16 million) in Concord Medical’s subsidiary Beijing Meizhong Jiahe Hospital Management Co., Ltd.
James Watson, the Nobel laureate who co-discovered the structure of DNA, has thrown his support behind a life science research center being established by the Shenzhen city government. In fact, the 90-year-old scientist will work at the facility, according to Chinese media.
Chinese healthcare provider iKang Healthcare Group, Inc. (NASDAQ:KANG）announced that a consortium led by Alibaba Investment Limited and Jack Ma co-founded Yunfeng Capital, has proposed a all-cash transaction to privatize the US$1.29 billion company.
Chinese cell therapy company JW Therapeutics (Shanghai) Co., Ltd announced that it has raised a US$90 million series A found led by investors Temasek, Sequoia Capital China, and YuanMing Capital, a Beijing-based US dollar fund focusing on investments in pharmaceutical research and development, medical devices and services in both China and the U.S.
Matrix Partners China, a joint venture fund between U.S. venture capital firm Matrix Partners and its Chinese partners, has led a RMB100 million (US$15.8 million) financing round in Chinese genetics testing and analyzing start-up 23Mofang.
U.S.-based cancer detection start-up Grail Inc. is reportedly planning an initial public offering on the Hong Kong Stock Exchange in what could be the first test of the city’s proposed duel-class listing system for tech companies.
Fosun International Ltd. (00656:HK) and London-based healthcare and life science company Arix Bioscience plc (LSE:ARIX) have jointly announced a strategic agreement to develop and commercialize new clinical therapies for patients with a focus on the Chinese markets.
Citic Capital-controlled Harbin Pharmaceutical Group Holding, known as Hayao, has agreed to invest US$300 million in U.S.-based health and wellness retailer GNC Holdings, becoming the single largest shareholder in NYSE-traded GNC.
American nutrition supplements company Herbalife Ltd. announced today it has created a “China Growth and Impact Investment Fund” to accelerate growth of its business in China.
U.S. pharmaceutical giant Pfizer has taken a financial stake and entered into a two-year research collaboration with NetVation DL Medicine, a privately held biotechnology company that is backed by Chinese Academy of Sciences.
Ping An Healthcare And Technology Co., Ltd., which operates the popular healthcare and medical mobile app Ping An Good Doctor, has been cleared for a US$5 billion initial public offering in Hong Kong.
Ping An Ventures, the direct investment arm of Ping An Insurance (Group) Company of China, Ltd., has led a US$100 million series A round in Philadelphia-based biotherapeutics company Tmunity Therapeutics.
Chinese investment banking firm CEC Capital Group has announced the promotion of John Song, Gang Li and Zack Zhang to partner, as the firm aims to broaden and deepen its coverage to a new class of rising Chinese enterprises.
Shenzhen Capital Group Co., Ltd, Minsheng Life Insurance and Share Capital have led a RMB400 million (US$62 million) series B round in Suzhou Zelgen Biosciences Co., Ltd., a Chinese biopharmaceutical company.
Chinese private equity firm C-Bridge Capital has teamed up with Suzhou bio-medical and medical high-tech park BioBAY in leading a US$38 million series A round in CMAB BioPharm, a contract development and manufacturing organization (CDMO) providing comprehensive pharmaceutical services to biopharma companies.
Vision Plus Capital, a Hangzhou-based venture capital firm, has led a RMB200 million (US$30 million) series B round in Etong Healthcare, a third-party health examination service provider.
Ping An Capital, the core equity investment platform of one of the largest Chinese insurers Ping An Insurance Group, has led an over RMB800 million (US$121 million) investment deal in Fullerton Healthcare Corporation Ltd., a Singapore-based provider of corporate healthcare solutions across Asia Pacific, according to an announcement issued by Fullerton Healthcare.
Preceptis Medical Inc., a U.S.-based pediatric surgical technologies developer, has reached the initial closing of its series B financing round led by a group of unnamed Chinese private investors.
SDIC Venture Capital Management, a subsidiary of State Development & Investment Corp (SDIC), has led a new funding round worth up to RMB507 million (US$76 million) in Zensun (Shanghai) Sci & Tech Co., Ltd., a biopharmaceutical company listed on the ChiNext board in Shenzhen.
Chinese healthcare-focused investment firm 6 Dimensions Capital and Sijia Jianxin Fund have led a US$28 million series B round in AnchorDX Corp., a Guangzhou city-headquartered precision medicine start-up.
Dah Chong Hong Holdings Ltd., a Hong Kong-listed distributor and dealer of motor vehicles in Greater China, said it plans to partner with its parent company that is a subsidiary of CITIC Ltd. to establish an investment fund to back consumer and healthcare companies.
China’s healthcare sector is seeing a flood of new capital from from non-professional investors such as Chinese coal mining and factory bosses, according to James Huang, a managing partner at Kleiner Perkins Caufield & Byers (KPCB) China, who focuses on life sciences. As a result, valuations have become excessive, forcing more experienced investors to adopt new strategies to get ahead of the "dumb money."
XW Laboratories Inc., a Chinese biopharmaceutical research and development company focused on neurological disorders, has raised US$17.5 million in a series B financing led by Elements Capital and WI Harper. New investo KTB Network, and all existing investors KPCB China, Johnson & Johnson Innovation and WuXi Venture, also participated.
Chinese biopharmaceutical company Zai Lab Ltd., backed by Chinese venture capital firms including Advantech, OrbiMed Asia Partners and Qiming Venture Partners, has completed an initial public offering on the NASDAQ in New York, raising approximately US$150 million in total.
China Healthcare Investor Forum 2017, hosted by China Money Network and sponsored by Ernst & Young, was successfully held on September 19 at the Shanghai World Financial Center with four prominent speakers discussing investment opportunities and challenges in China’s booming healthcare sector.
Healthcare-dedicated investment firm OrbiMed has closed its third Asia-focused private equity fund, OrbiMed Asia Partners III, LP, with approximately US$551 million in capital commitments.
Eight Roads Ventures has launched its first dedicated China healthcare fund in a move that reflects continued focus of healthcare investments by Chinese venture investors.
Tencent Holdings Ltd. and BlueRun Ventures have led a RMB160 million (US$24 million) series A round in Shuidi, a crowdfunding platform within Tencent’s WeChat mobile app that helps people gain financial assistance to cover healthcare bills.